Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.

Orchestra BioMed, Inc., on Sept. 4 announced it received CE mark approval for its Moderato implantable pulse generation system, which delivers the company’s trademarked cardiac neuromodulation therapy to patients while simultaneously acting as a pacemaker.

When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.

MEDNAX, Inc. (NYSE: MD) and MEDNAX Radiology Solutions, one of the nation’s largest radiology practices, announced that Chief Medical Officer, Ricardo C. Cury, MD, FSCCT, will present at the 14th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) at the Baltimore Marriott Waterfront in Baltimore, Md. today.

Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.

Royal Philips has rolled out the latest update for its EPIQ CVx and EPIQ CVxi cardiac ultrasound systems, expanding to include automated applications for 2D assessment of the heart and robust 3D measurements of right ventricular volume and ejection fraction.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.